192 Biosynthesis of ilamycins featuring unusual building blocks and engineered production of enhanced anti-tuberculosis agents.

191 Plasmonic silver nanoshells for drug and metabolite detection.

190 Synergy of synthesis, computation and NMR reveals correct baulamycin structures.

189 Development of a Novel Lead that Targets M. tuberculosis Polyketide Synthase 13.

188 A novel humanized mouse lacking murine P450 oxidoreductase for studying human drug metabolism.

187 Click chemistry enables preclinical evaluation of targeted epigenetic therapies.

186 Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment.

185 A Cryptosporidium PI(4)K inhibitor is a drug candidate for cryptosporidiosis.

184 Predictive compound accumulation rules yield a broad-spectrum antibiotic.

183 Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab.

182 Potent neuroprotection after stroke afforded by a double-knot spider-venom peptide that inhibits acid-sensing ion channel 1a.

181 The druggable genome and support for target identification and validation in drug development.

180 Systemic delivery of factor IX messenger RNA for protein replacement therapy.

179 CD6 as a potential target for treating multiple sclerosis.

178 A nontoxic pain killer designed by modeling of pathological receptor conformations.

177 Pharmacologic inhibition of Hsp90 to prevent GLT-1 degradation as an effective therapy for epilepsy.

176 Allosteric “beta-blocker” isolated from a DNA-encoded small molecule library.

175 Drug discovery for Diamond-Blackfan anemia using reprogrammed hematopoietic progenitors.

174 Thioredoxin reverses age-related hypertension by chronically improving vascular redox and restoring eNOS function.

173 A Highly Durable RNAi Therapeutic Inhibitor of PCSK9.

Free Images for Presentation: sunipix SUNIPIX